FROM THE BMJ
The study was supported by a grant from the National Institute for Health Research. The investigators had no relevant disclosures.
SOURCE: Vinogradova Y et al. BMJ 2018; 362:K2505.
© Frontline Medical Communications 2018-2021. Reprinted with permission, all rights reserved.
The monoclonal antibody bentracimab, which can rapidly reverse ticagrelor, was found effective and safe in an FDA-requested interim analysis of a phase 3 trial.
Cerebrovascular protection was far better on DOACs after catheter ablation for VT or extrasystoles in the trial and may yet be further improved.
Medicare Part D spending since 2011 has far outpaced growth in the use of oral anticoagulants.
The meta-analysis of more than 4,000 patients also showed thrombotic events were more frequent with andexanet than with 4PCC or idarucizumab.
